-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Physical science Recently, the team of Prof.
Liu Zhuang and Prof.
Cheng Liang of Soochow University prepared calcium hydride nanoparticles (nano-CaH2) by liquid phase exfoliation method to realize hydrogen-immune synergistic therapy, which can effectively inhibit tumor growth
.
In cooperation with Professor Ni Caifang of the Interventional Department of the First People's Hospital Affiliated to Soochow University, the combined treatment of in situ liver cancer with hydrogen and embolization has been effectively realized
.
On December 13, 2021, the research results were published in the Cell Press journal Chem under the title "Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy"
.
▲Long press the picture to identify the QR code to read the original text Hydrogen (H2), as an endogenous gas, has significant physiological/pathological regulation functions
.
Over the past decade, the effectiveness of hydrogen therapy in anti-inflammatory and antitumor applications has been demonstrated, and hydrogen formulations such as hydrogen-rich water/hydrogen-rich salts have been used in clinical trials for diseases such as inflammation
.
The main mechanism of hydrogen anti-cancer is that hydrogen molecules can inhibit the energy metabolism of cancer cells, inhibit the expression of vascular endothelial growth factor, and activate the immune response of the system
.
However, currently commonly used hydrogen delivery strategies, such as hydrogen-rich water (H2-water, oral), hydrogen-rich salt (H2-saline, intravenous drip), hydrogen-rich (H2-gas, inhalation), etc.
, are difficult to achieve local therapeutic effects.
threshold
.
Therefore, there is a need to develop novel hydrogen delivery strategies for efficient, controllable and on-demand delivery of hydrogen
.
Calcium hydride (CaH2) materials, as a portable hydrogen source, can efficiently provide high-purity hydrogen, bringing an opportunity for the development of a new generation of hydrogen delivery systems
.
Recently, the team of Professor Liu Zhuang and Professor Cheng Liang of Soochow University prepared calcium hydride nanoparticles (nano-CaH2) by a liquid phase exfoliation method, dispersed them into low molecular weight polyethylene glycol (PEG200) and injected them locally into the tumor.
-CaH2 is decomposed in situ to generate hydroxide ions (OH−), calcium ions (Ca2+) and hydrogen gas (H2), etc.
to neutralize the weakly acidic microenvironment of the tumor, induce local calcium overload, realize hydrogen-immune synergistic therapy, and effectively inhibit the microenvironment of small tumors.
Growth of subcutaneous xenografts in mice
.
The main mechanisms of action are: (1) production of OH− to neutralize the weak acidity of the tumor to reshape the immunosuppressive microenvironment; (2) increased local Ca2+ triggers tumor calcium overload and calcium death; (3) release of H2 triggers hydrogen therapy and anti-tumor effects.
Tumor immune response
.
In addition, the team cooperated with Professor Ni Caifang from the Interventional Department of the First People's Hospital Affiliated to Soochow University to compound nano-CaH2 and clinical Lipiodol embolic agent to prepare a calcium hydride-lipiodol (nano-CaH2-Lipiodol) compound embolic agent.
The combined hydrogen-embolization therapy for in situ liver cancer in rabbits was effectively realized, which provided a theoretical basis for the development of a new generation of multifunctional hepatic artery embolization agents
.
Figure 1: Nano-CaH2 is used for combined hydrogen-immunotherapy of subcutaneous tumors in mice and interventional embolization of orthotopic liver cancer in rabbits
.
Related paper information The original text of the paper was published in the journal Chem, a subsidiary of CellPress Cell Press.
Liu Zhuang and Prof.
Cheng Liang of Soochow University prepared calcium hydride nanoparticles (nano-CaH2) by liquid phase exfoliation method to realize hydrogen-immune synergistic therapy, which can effectively inhibit tumor growth
.
In cooperation with Professor Ni Caifang of the Interventional Department of the First People's Hospital Affiliated to Soochow University, the combined treatment of in situ liver cancer with hydrogen and embolization has been effectively realized
.
On December 13, 2021, the research results were published in the Cell Press journal Chem under the title "Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy"
.
▲Long press the picture to identify the QR code to read the original text Hydrogen (H2), as an endogenous gas, has significant physiological/pathological regulation functions
.
Over the past decade, the effectiveness of hydrogen therapy in anti-inflammatory and antitumor applications has been demonstrated, and hydrogen formulations such as hydrogen-rich water/hydrogen-rich salts have been used in clinical trials for diseases such as inflammation
.
The main mechanism of hydrogen anti-cancer is that hydrogen molecules can inhibit the energy metabolism of cancer cells, inhibit the expression of vascular endothelial growth factor, and activate the immune response of the system
.
However, currently commonly used hydrogen delivery strategies, such as hydrogen-rich water (H2-water, oral), hydrogen-rich salt (H2-saline, intravenous drip), hydrogen-rich (H2-gas, inhalation), etc.
, are difficult to achieve local therapeutic effects.
threshold
.
Therefore, there is a need to develop novel hydrogen delivery strategies for efficient, controllable and on-demand delivery of hydrogen
.
Calcium hydride (CaH2) materials, as a portable hydrogen source, can efficiently provide high-purity hydrogen, bringing an opportunity for the development of a new generation of hydrogen delivery systems
.
Recently, the team of Professor Liu Zhuang and Professor Cheng Liang of Soochow University prepared calcium hydride nanoparticles (nano-CaH2) by a liquid phase exfoliation method, dispersed them into low molecular weight polyethylene glycol (PEG200) and injected them locally into the tumor.
-CaH2 is decomposed in situ to generate hydroxide ions (OH−), calcium ions (Ca2+) and hydrogen gas (H2), etc.
to neutralize the weakly acidic microenvironment of the tumor, induce local calcium overload, realize hydrogen-immune synergistic therapy, and effectively inhibit the microenvironment of small tumors.
Growth of subcutaneous xenografts in mice
.
The main mechanisms of action are: (1) production of OH− to neutralize the weak acidity of the tumor to reshape the immunosuppressive microenvironment; (2) increased local Ca2+ triggers tumor calcium overload and calcium death; (3) release of H2 triggers hydrogen therapy and anti-tumor effects.
Tumor immune response
.
In addition, the team cooperated with Professor Ni Caifang from the Interventional Department of the First People's Hospital Affiliated to Soochow University to compound nano-CaH2 and clinical Lipiodol embolic agent to prepare a calcium hydride-lipiodol (nano-CaH2-Lipiodol) compound embolic agent.
The combined hydrogen-embolization therapy for in situ liver cancer in rabbits was effectively realized, which provided a theoretical basis for the development of a new generation of multifunctional hepatic artery embolization agents
.
Figure 1: Nano-CaH2 is used for combined hydrogen-immunotherapy of subcutaneous tumors in mice and interventional embolization of orthotopic liver cancer in rabbits
.
Related paper information The original text of the paper was published in the journal Chem, a subsidiary of CellPress Cell Press.
